Extended Data Fig. 7: 6-month follow-up for post-COVID syndrome (PCS) in responders to nicotinamide in the acute phase who were at risk for developing PCS.
The box plots depict the PCS scores of 105 participants at risk for developing PCS with a PCS score >0, who had shown improvement in the primary endpoint or one of the three key secondary endpoints in the acute phase of the disease (nicotinamide: n = 48 [19 males, 29 females]; placebo: n = 57 [15 males, 42 females]). The median PCS score was 6.5 (quartile [Q]1: 3.5, Q3: 11.0) in participants who had received nicotinamide (males: 6.5 [3.5; 11.5], females: 6.5 [3.5; 11.0]) and 10.5 (Q1: 5.5, Q3: 17.0) in participants who had received placebo (males: 10.5 [5.25; 11.0], females: 10.75 [6.5; 17.0]). The mean PCS score ± s.e. was 8.33 ± 0.84 with nicotinamide (males: 8.37 ± 1.34, females: 8.31 ± 1.09) and 11.82 ± 1.03 with placebo (males: 9.67 ± 1.37, females: 12.60 ± 1.29). Box plots show the median (center line), interquartile range (IQR, box), 1.5x IQR (whiskers) and outliers (points). The means (red points) ± standard error (red whiskers) are shown within the box. Two-sided, unadjusted t-test for independent groups.
